GoodRx (NASDAQ:GDRX) Rating Increased to Strong-Buy at Raymond James

Raymond James upgraded shares of GoodRx (NASDAQ:GDRX – Free Report) from an outperform rating to a strong-buy rating in a report issued on Friday morning, Marketbeat reports. The firm currently has $10.00 price objective on the stock. Other equities research analysts have also issued reports about the company. TD Cowen lifted their target price on […]

Leave a Reply

Your email address will not be published.

Previous post Getting to Know You: Brad Walker, founder of Adaptive Accountancy
Next post Augusta Gold (BFGCD) versus The Competition Financial Survey